MaxCyte Forum: Powering Cell Engineering Forward – Efficacy and Safety in Advanced Therapies

MaxCyte is organizing an exclusive pre-conference forum meeting in Seville, Spain, to be held the afternoon of October 6, 2025 before the European Society of Gene & Cell Therapy (ESGCT) Annual Congress (October, 7–10). This half-day event aims to bring together scientists passionate about bringing cell & gene therapy development forward. This event will foster scientific exchange, community building, and discussions around advancements in non-viral cell engineering technologies.

Key objectives of the meeting include:

• Providing a science-driven forum for existing and prospective users to share insights, best practices, and case studies.
• Facilitating open roundtable discussions on critical topics such as GMP processes, regulatory considerations, and scalability challenges in cell and gene therapy. Thus, strengthening user engagement and collaboration opportunities
• Meet the MaxCyte^® team and receive hands-on training with an ExPERT^TM electroporator.

The proposed program will feature keynote presentations by leading speakers, scientific case studies, interactive roundtable discussions, and a closing networking reception showcasing local Spanish tapas.

The meeting will also feature the following topics and contributors:

Screening for Next-Generation CARs and TCRs

• Cosmas Arnold, PhD, Christoph Bock Lab, Center for Molecular Medicine (CeMM), Vienna, Austria

Clinical-Grade Transposon Engineering

• Omkar Vikram Panchal, PhD, Zoltan Ivics Lab, Department of Clinical Gene Transfer, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
• Francesco Manfredi, PhD, Chiara Magnani Lab, Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland
• Begoña Diez Cabezas, PhD, CIEMAT/CIBERER/IIS-FJD, CliniStem GMP Facility, Madrid, Spain

General Challenges in Cell Therapy Process Development

• Katrin Mestermann, PhD, Michael Hudecek Lab, University Hospital Wurzburg, Germany
• Valentin Do Sacramento, PhD, Cimeio Therapeutics, Basel, Switzerland

Gene Editing Off-Target Risk Assessment

• Stephanie Cherqui, PhD, University of California San Diego & Papillon Therapeutics, San Diego, CA
• Colin Exline, PhD, Papillon Therapeutics, San Diego, CA
• TBC, T-Knife Therapeutics, Berlin, Germany

Please note: Registration for this event is by invitation. A selection of registrants will be made based on interest and relevance to the program. Formal invitations will be sent once your interest has been reviewed.

Disclaimer: Photography and Recording Notice

By registering for this event, you acknowledge and agree that photographs and video recordings may be taken during the course of the event, including during presentation sessions. These materials may be used by MaxCyte, Inc. for promotional and educational purposes, including in print, digital, and online formats.

By submitting this form, you give your consent to be photographed and recorded, and you grant permission for these materials to be used as described.